Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2476 participants
OBSERVATIONAL
2019-02-28
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NCI UNC Project ESCC
NCT03206125
Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
NCT03223662
Study of Epigallocatechin-3-gallate (EGCG) for Supportive and Symptomatic Management in Patients With Esophageal Cancer
NCT05039983
Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer
NCT01858805
Role of Esophagectomy in Complete Responders to CCRT
NCT01740375
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Aim 1: To describe the types of treatments administered for all patients diagnosed with EC at participating AfrECC sites, including chemotherapeutic regimens, radiation therapy, chemo-radiotherapy, esophageal stenting, esophagectomy, and basic supportive care.
Aim 2: To evaluate the effect of different EC treatment modalities on patient reported outcomes during and after completion of treatment.
Aim 3: To measure the effect of different treatment modalities on overall survival.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with Esophageal Cancer
Participants with esophageal cancer will be administered questionnaires, and medical charts will be accessed to collect study related data.
Assessment of patient-reported outcomes (PROs)
Questionnaires will be administered to participants
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Assessment of patient-reported outcomes (PROs)
Questionnaires will be administered to participants
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 years of age or older;
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Westat
OTHER
African Esophageal Cancer Consortium (AfrECC)
UNKNOWN
National Cancer Institute (NCI)
NIH
Celgene Corporation
INDUSTRY
University of California, San Francisco
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Geoffrey Buckle, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Katherine Van Loon, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tenwek Hospital
Bomet, , Kenya
Moi Teaching and Referral Hospital
Eldoret, , Kenya
Kamuzu Central Hospital
Lilongwe, , Malawi
Muhimbili National Hospital
Dar es Salaam, , Tanzania
Ocean Road Cancer Institute
Dar es Salaam, , Tanzania
Kilimanjaro Christian Medical Centre
Moshi, , Tanzania
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Buckle GC, Mrema A, Mwachiro M, Ringo Y, Selekwa M, Mulima G, Some FF, Mmbaga BT, Mody GN, Zhang L, Paciorek A, Akoko L, Ayuo P, Burgert S, Bukusi E, Charles A, Chepkemoi W, Chesumbai G, Kaimila B, Kenseko A, Kibwana KS, Koech D, Macharia C, Moirana EN, Mushi BP, Mremi A, Mwaiselage J, Mwanga A, Ndumbalo J, Nvakunga G, Ngoma M, Oduor M, Oloo M, Opakas J, Parker R, Seno S, Salima A, Servent F, Wandera A, Westmoreland KD, White RE, Williams B, Mmbaga EJ, Van Loon K; of the African Esophageal Cancer Consortium (AfrECC). Treatment outcomes of esophageal cancer in Eastern Africa: protocol of a multi-center, prospective, observational, open cohort study. BMC Cancer. 2022 Jan 19;22(1):82. doi: 10.1186/s12885-021-09124-5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21455
Identifier Type: OTHER
Identifier Source: secondary_id
184510
Identifier Type: OTHER
Identifier Source: secondary_id
214520
Identifier Type: OTHER
Identifier Source: secondary_id
204510
Identifier Type: OTHER
Identifier Source: secondary_id
184515
Identifier Type: OTHER
Identifier Source: secondary_id
TOEC-AfrECC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.